Page 2 - Detect Test News Today

The test from Quest Diagnostics looks at a certain brain protein is known to contribute to the condition.

The test from Quest Diagnostics looks at a certain brain protein is known to contribute to the condition.

/PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the leader in diagnostic information services, today announced the availability of the AD-Detect™ Test for...

(RTTNews) - Quest Diagnostics (DGX) announced the availability of the AD-Detect Test for Alzheimers Disease on questhealth.com. AD-Detect is a sc...

Quest Diagnostics announced Monday that it launched the first direct-to-consumer blood test to help people assess their risk of developing Alzheimer's disease.

Mirae Asset Global Investments Co. Ltd. raised its position in Exact Sciences Co. (NASDAQ:EXAS – Get Rating) by 19.4% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 112,740 shares of the medical research company’s stock after buying an additional 18,357 shares during the quarter. Mirae Asset Global […]

Exact Sciences (NASDAQ:EXAS – Get Rating) and Viridian Therapeutics (NASDAQ:VRDN – Get Rating) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership. Insider and Institutional Ownership 94.5% of Exact Sciences shares are […]

Viridian Therapeutics (NASDAQ:VRDN – Get Rating) and Exact Sciences (NASDAQ:EXAS – Get Rating) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability. Volatility & Risk Viridian Therapeutics has a beta of 1.13, […]

Exact Sciences (NASDAQ:EXAS – Get Rating) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Saturday. Several other equities research analysts have also recently weighed in on EXAS. The Goldman Sachs Group dropped their price target on shares of Exact Sciences from $100.00 to $85.00 and […]

Exact Sciences (NASDAQ:EXAS – Get Rating) and Genetron (NASDAQ:GTH – Get Rating) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings. Institutional and Insider Ownership 94.5% of Exact Sciences shares are held […]